Tempus AI signs data deals worth up to $192.5 million with Bristol-Myers Squibb, Pathos AI
Bitget2026/10/23 13:05- Tempus AI announced Oct. 23, 2026, agreements with Bristol-Myers Squibb and Pathos AI worth up to $192.5 million over approximately five years.
- The Oct. 14 oncology data agreement provides $137.5 million in fixed payments from Bristol-Myers Squibb through Dec. 31, 2031.
- Pathos AI’s Oct. 22 neurology agreement provides up to $55 million over five years, including $5 million for record updates.
- Neurology data fees depend on delivery of up to 500,000 patient records at $100 each, targeting 100,000 records annually.
- Bristol-Myers Squibb may terminate the oncology agreement with 12 months’ written notice and payment of a substantial termination fee.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.
SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.
Crypto prices
More
